Lantheus Holdings, Inc. Proceeds from Sale of Restricted Investments
Lantheus Holdings, Inc. (LNTH) reported Proceeds from Sale of Restricted Investments of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfRestrictedInvestments · last filed 2019-02-20
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for the quarter ending 2016-12-31 was $0.00.
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for the quarter ending 2016-09-30 was $0.00.
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for the quarter ending 2016-06-30 was $0.00.
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for fiscal 2018 was $0.00.
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for fiscal 2016 was $74.00K.
- Lantheus Holdings, Inc. proceeds from sale of restricted investments for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
| Period end | Proceeds from Sale of Restricted Investments 3 month | Proceeds from Sale of Restricted Investments 6 month | Proceeds from Sale of Restricted Investments 9 month | Proceeds from Sale of Restricted Investments 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-20 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-20 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-02 | $0.00 derived: sum of 2 quarters · filed 2019-02-20 | $0.00 derived: sum of 3 quarters · filed 2019-02-20 | $0.00 derived: sum of 4 quarters · filed 2019-02-20 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $0.00 derived: sum of 2 quarters · filed 2019-02-20 | $0.00 derived: sum of 3 quarters · filed 2019-02-20 | $74.00K 10-K · filed 2019-02-20 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $0.00 derived: sum of 2 quarters · filed 2016-11-01 | $74.00K 10-Q · filed 2016-11-01 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $74.00K 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | $74.00K 10-Q · filed 2017-05-02 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-26 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $228.00K 10-K · filed 2017-02-23 | ||
| 2014-09-30 | $228.00K 10-Q · filed 2015-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |